Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A newly developed drug molecule doesn't just fit its cancer-linked protein target — it reshapes it. Researchers at the University at Buffalo found that the molecule causes a flexible protein loop in p38 delta to wrap snugly around it, achieving a 12,000-fold improvement in selectivity and 110-fold greater potency than existing compounds. The discovery could open new doors in drug design.
Instead of designing a molecule to fit a protein, what if you designed one that makes the protein fit it? That's exactly what researchers at the University at Buffalo have done with a new inhibitor targeting p38 delta — a protein implicated in cancer that has long been notoriously difficult to drug selectively. Published in Angewandte Chemie International Edition, the study reveals that the molecule triggers a "bump-kink" effect: it bumps against a flexible loop in the protein, causing the loop to kink and wrap tightly around the molecule in a self-encapsulating embrace.
The key to this unusual behavior lies in a distinctive amino acid called histidine 30, located far from the actual binding site — a region researchers would typically overlook. This distant feature helps stabilize the structural change, enabling the molecule to achieve remarkable precision.
By the Numbers:
Why it matters: Better selectivity means a drug is more likely to hit its intended target while leaving the rest of the body alone — reducing toxic side effects. This novel "make the target adapt" strategy could serve as a blueprint for developing drugs against previously "undruggable" proteins.
